Fiorini C, Abdulhay NJ, McFarland SK, et al. Developmentally-faithful and effective human erythropoiesis in immunodeficient and Kit mutant mice. Am J Hematol. 2017;92(9):E513-E519. doi:10.1002/ajh.24805
Tothova Z, Krill-Burger JM, Popova KD, et al. Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell. 2017;21(4):547-555.e8. doi:10.1016/j.stem.2017.07.015
Lucas D, O’Leary HA, Ebert BL, Cowan CA, Tremblay CS. Utility of CRISPR/Cas9 systems in hematology research. Exp Hematol. 2017;54:1-3. doi:10.1016/j.exphem.2017.06.006
Buenrostro JD, Corces R, Lareau CA, et al. Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation. Cell. 2018;173(6):1535-1548.e16. doi:10.1016/j.cell.2018.03.074
Hanna GJ, Kofman ER, Shazib MA, et al. Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018;81:1-9. doi:10.1016/j.oraloncology.2018.04.007
Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32(25):2691-8. doi:10.1200/JCO.2013.52.3381
Kalaitzidis D, Sykes SM, Wang Z, et al. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell. 2012;11(3):429-39. doi:10.1016/j.stem.2012.06.009
Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143-53. doi:10.1056/NEJMoa1601202
Chen CZ, Li M, de Graaf D, et al. Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc Natl Acad Sci U S A. 2002;99(24):15468-73. doi:10.1073/pnas.202614899